- 100% success rate in CD34+ stem cell mobilization observed in interim analysis.
- GPC-100 offers faster treatment administration compared to current FDA-approved alternatives.
- Patient recruitment for the Phase 2 trial is set to conclude by the end of April 2025.
Exicure, Inc. (XCUR, Financial) is nearing the completion of its Phase 2 study of the small molecule CXCR4 inhibitor GPC-100 (burixafor) focused on mobilizing stem cells in multiple myeloma patients undergoing autologous stem cell transplants. This open-label, multi-center trial involves the administration of GPC-100 in combination with propranolol and G-CSF.
Interim results revealed a 100% success rate in CD34+ stem cell mobilization among the first 10 patients, including those previously treated with daratumumab. This finding was presented at the 2024 American Society of Hematology (ASH) Annual Meeting. The study highlights GPC-100's capability for same-day administration and leukapheresis, providing quicker treatment compared to FDA-approved agents such as plerixafor and motixafortide, which require overnight pre-treatment.
Engraftment times recorded a median of 11 days for neutrophils and 14 days for platelets, aligning with standard care expectations. The trial expects to complete patient recruitment, having currently dosed 19 patients, by the end of April 2025.
